%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Tejiokem, M. C.
%A Desselas, Emilie
%A Noumsi, T. J.
%A Ndongo, F. A.
%A Ndiang, S. T.
%A Fossi, M. A.
%A Guemkam, G.
%A Tekougang, B. Z. K.
%A Tagnouokam-Ngoupo, P. A.
%A Penda, I. C.
%A Faye, A.
%A Warszawski, J.
%T Pre- and post-vaccination measles antibody and persistence up to 5 years of age among early ART-treated HIV-infected, HIV-exposed Uninfected and HIV-unexposed children in Cameroon
%D 2025
%L fdi:010094237
%G ENG
%J Vaccines
%K measles humoral immunity ; persistence of measles antibodies ; pre-measles ; vaccine antibodies ; early treated HIV-infected ; HIV-exposed uninfected ; HIV-unexposed uninfected ; low- and middle-income countries ; real life conditions
%K CAMEROUN
%M ISI:001516140600001
%N 6
%P 584 [16 ]
%R 10.3390/vaccines13060584
%U https://www.documentation.ird.fr/hor/fdi:010094237
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2025-07/010094237.pdf
%V 13
%W Horizon (IRD)
%X Background/Objective: Variations in measles vaccine antibody response by age and HIV status have been reported. This study assessed measles pre-vaccination status and compared humoral response durability over the first five years of life among HIV-infected (HI) children on early treatment, HIV-exposed uninfected (HEU), and HIV-unexposed uninfected (HUU) children within the ANRS 12225-Pediacam III cohort in Cameroon. Methods: Measles vaccine (MCV) was administered at 6 and 9 months for HIV-exposed infants and at 9 months for HIV-unexposed infants, followed by a measles-mumps-rubella (MMR) dose at 15 months for all. Measles antibody titers were measured pre-vaccination, 1-6 months post-MCV doses, and annually until age 5 using ELISA (Enzygnost, Dade Behring). Results: A total of 496 children were included: 143 HI (median age at cART initiation: 4.2 months, (IQR: 3.2-5.6)), 180 HEU, and 173 HUU. Of these, 456 children were tested pre-vaccination (median age: 6.1 months, IQR: 5.6-6.8), with 6.1% (95% CI: 4.1-8.6) seropositive to measles antibodies, with differences across groups. At 18.4 months (IQR: 18.1-19.9), seropositivity rates were 96.7% (59/61) in HI, 96.8% (90/93) in HEU, and 100% (111/111) in HUU groups. For children following the 6 + 9 + 15-month or 9 + 15-month MCV schedules, seropositivity at 18, 36, 48, and 60 months was 96%, 89%, 87%, and 88%, respectively, with no significant differences between groups. Conclusions: Early cART initiation in HI children may result in a robust initial measles antibody response, with comparable persistence of antibody titers across all groups up to five years.
%$ 050 ; 052